Affordable Access

Loss of promyelocytic leukemia protein in human gastric cancers

Authors
Journal
Cancer Letters
0304-3835
Publisher
Elsevier
Publication Date
Volume
247
Issue
1
Identifiers
DOI: 10.1016/j.canlet.2006.03.034
Keywords
  • Pml Protein
  • Gastric Cancers
  • Immunohistochemistry
  • Tissue Array Analysis
  • Proteasome Inhibitor
  • Survival Analysis
Disciplines
  • Biology
  • Chemistry

Abstract

Abstract To clarify the clinical implications of promyelocytic leukemia (PML) expression in gastric carcinomas, the expression of PML was analyzed in large series of gastric carcinoma by immunohistochemistry, western blotting and reverse transcription-PCR. PML protein expression was reduced or abolished in gastric carcinomas (31.7 and 10.6%, respectively) by immunohistochemistry. PML protein loss was associated with more lymphatic invasion, higher pTNM stage, and worse patient survival. Only one gastric carcinoma cell line showed loss of PML, and the PML protein re-appeared after the treatment of proteasome inhibitor in this cell line. We conclude that PML protein loss occurs in a minority of gastric carcinomas during carcinogenesis and progression, and suggest the proteasome-dependent pathway as a mechanism of PML protein loss.

There are no comments yet on this publication. Be the first to share your thoughts.